204 related articles for article (PubMed ID: 36272969)
1. Two-Year Analysis of a New Oral Testosterone Undecanoate (TU) Formulation in Hypogonadal Men: Efficacy, Impact on Psychosexual Function, and Safety.
Honig S; Gittelman M; Kaminetsky J; Wang C; Amory JK; Rohowsky N; Dudley RE; Woun Seo B; Newmark J; Swerdloff R
J Sex Med; 2022 Dec; 19(12):1750-1758. PubMed ID: 36272969
[TBL] [Abstract][Full Text] [Related]
2. A New Oral Testosterone Undecanoate Formulation Restores Testosterone to Normal Concentrations in Hypogonadal Men.
Swerdloff RS; Wang C; White WB; Kaminetsky J; Gittelman MC; Longstreth JA; Dudley RE; Danoff TM
J Clin Endocrinol Metab; 2020 Aug; 105(8):2515-31. PubMed ID: 32382745
[TBL] [Abstract][Full Text] [Related]
3. A new oral testosterone undecanoate therapy comes of age for the treatment of hypogonadal men.
Swerdloff RS; Dudley RE
Ther Adv Urol; 2020; 12():1756287220937232. PubMed ID: 32655691
[TBL] [Abstract][Full Text] [Related]
4. Testosterone replacement therapy: improved sexual desire and erectile function in men with type 2 diabetes following a 30-week randomized placebo-controlled study.
Hackett G; Cole N; Saghir A; Jones P; Strange RC; Ramachandran S
Andrology; 2017 Sep; 5(5):905-913. PubMed ID: 28771964
[TBL] [Abstract][Full Text] [Related]
5. Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes.
Hackett G; Cole N; Bhartia M; Kennedy D; Raju J; Wilkinson P
J Sex Med; 2013 Jun; 10(6):1612-27. PubMed ID: 23551886
[TBL] [Abstract][Full Text] [Related]
6. Testosterone replacement therapy does not promote priapism in hypogonadal men with sickle cell disease: 12-month safety report.
Morrison BF; Reid M; Madden W; Burnett AL
Andrology; 2013 Jul; 1(4):576-82. PubMed ID: 23606509
[TBL] [Abstract][Full Text] [Related]
7. Comparison of a new long-acting testosterone undecanoate formulation vs testosterone enanthate for intramuscular androgen therapy in male hypogonadism.
Minnemann T; Schubert M; Freude S; Hübler D; Gouni-Berthold I; Schumann C; Christoph A; Oettel M; Ernst M; Mellinger U; Krone W; Jockenhövel F
J Endocrinol Invest; 2008 Aug; 31(8):718-23. PubMed ID: 18852533
[TBL] [Abstract][Full Text] [Related]
8. Testosterone undecanoate improves sexual function in men with type 2 diabetes and severe hypogonadism: results from a 30-week randomized placebo-controlled study.
Hackett G; Cole N; Saghir A; Jones P; Strange RC; Ramachandran S
BJU Int; 2016 Nov; 118(5):804-813. PubMed ID: 27124889
[TBL] [Abstract][Full Text] [Related]
9. Adding liraglutide to lifestyle changes, metformin and testosterone therapy boosts erectile function in diabetic obese men with overt hypogonadism.
Giagulli VA; Carbone MD; Ramunni MI; Licchelli B; De Pergola G; Sabbà C; Guastamacchia E; Triggiani V
Andrology; 2015 Nov; 3(6):1094-103. PubMed ID: 26447645
[TBL] [Abstract][Full Text] [Related]
10. Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism.
Schubert M; Minnemann T; Hübler D; Rouskova D; Christoph A; Oettel M; Ernst M; Mellinger U; Krone W; Jockenhövel F
J Clin Endocrinol Metab; 2004 Nov; 89(11):5429-34. PubMed ID: 15531493
[TBL] [Abstract][Full Text] [Related]
11. Comparison of long-acting testosterone undecanoate formulation versus testosterone enanthate on sexual function and mood in hypogonadal men.
Jockenhövel F; Minnemann T; Schubert M; Freude S; Hübler D; Schumann C; Christoph A; Ernst M
Eur J Endocrinol; 2009 May; 160(5):815-9. PubMed ID: 19225035
[TBL] [Abstract][Full Text] [Related]
12. IPASS: a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 men.
Zitzmann M; Mattern A; Hanisch J; Gooren L; Jones H; Maggi M
J Sex Med; 2013 Feb; 10(2):579-88. PubMed ID: 22812645
[TBL] [Abstract][Full Text] [Related]
13. Validity and Clinically Meaningful Changes in the Psychosexual Daily Questionnaire and Derogatis Interview for Sexual Function Assessment: Results From the Testosterone Trials.
Wang C; Stephens-Shields AJ; DeRogatis LR; Cunningham GR; Swerdloff RS; Preston P; Cella D; Snyder PJ; Gill TM; Bhasin S; Matsumoto AM; Rosen RC
J Sex Med; 2018 Jul; 15(7):997-1009. PubMed ID: 29960633
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of two different testosterone undecanoate formulations in hypogonadal men with metabolic syndrome.
Aversa A; Bruzziches R; Francomano D; Spera G; Lenzi A
J Endocrinol Invest; 2010 Dec; 33(11):776-83. PubMed ID: 20220293
[TBL] [Abstract][Full Text] [Related]
15. Quality of Life and Sexual Function Benefits of Long-Term Testosterone Treatment: Longitudinal Results From the Registry of Hypogonadism in Men (RHYME).
Rosen RC; Wu F; Behre HM; Porst H; Meuleman EJH; Maggi M; Romero-Otero J; Martinez-Salamanca JI; Jones TH; Debruyne FMJ; Kurth KH; Hackett GI; Quinton R; Stroberg P; Reisman Y; Pescatori ES; Morales A; Bassas L; Cruz N; Cunningham GR; Wheaton OA;
J Sex Med; 2017 Sep; 14(9):1104-1115. PubMed ID: 28781213
[TBL] [Abstract][Full Text] [Related]
16. An oral lipidic native testosterone formulation that is absorbed independent of food.
Newell-Price J; Huatan H; Quirke J; Porter J; Daniel E; Mumdzic E; Voet B; Keevil B; Whitaker MJ; Ross RJ
Eur J Endocrinol; 2021 Oct; 185(5):607-615. PubMed ID: 34379604
[TBL] [Abstract][Full Text] [Related]
17. A phase III, single-arm, 6-month trial of a wide-dose range oral testosterone undecanoate product.
Bernstein JS; Dhingra OP
Ther Adv Urol; 2024; 16():17562872241241864. PubMed ID: 38606384
[TBL] [Abstract][Full Text] [Related]
18. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
Coward RM; Simhan J; Carson CC
BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
[TBL] [Abstract][Full Text] [Related]
19. Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a phase II study.
von Eckardstein S; Nieschlag E
J Androl; 2002; 23(3):419-25. PubMed ID: 12002444
[TBL] [Abstract][Full Text] [Related]
20. The efficacy and safety of testosterone undecanoate (Nebido(®)) in testosterone deficiency syndrome in Korean: a multicenter prospective study.
Moon DG; Park MG; Lee SW; Park K; Park JK; Kim SW; Park NC; Ahn TY; Paick JS; Seo JT; Yang DY; Lee JY; Kim JJ
J Sex Med; 2010 Jun; 7(6):2253-2260. PubMed ID: 20345732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
